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ABSTRACT 
Esther Olabosede Akinnagbe-Zusterzeel: Fluorine-19 (19F) magnetic resonance imaging of 
pulmonary ventilation, cell migration and inflammation 
(Under the direction of Yueh Z. Lee) 
 
Conventional 1H magnetic resonance imaging (MRI) has long been used in a variety of 
clinical applications.  Among other advantages, MRI lacks ionizing radiation while still 
providing high resolution images with significant soft-tissue contrast.  Advances in coil design 
and pulse sequencing have allowed for the adaptation of clinical scanners to fluorine-19 based 
MRI (19F MRI).  Well-understood to be inert and non-toxic, many commercially available 19F 
compounds can be introduced into subjects as tracing agents.  Resulting images have high signal-
to-noise ratios (SNR) due to minimal intrinsic 19F signal; any signal recorded originated from the 
introduced agent.  19F MRI presents several new opportunities to improve and create applications 
of an already versatile imaging modality.   
Pulmonary Imaging     As the need to understand the physiology of abnormal pulmonary 
conditions grows, so does the demand for quantitative lung function imaging methods.  The use 
of exogenous 19F gas along with improved pulse sequencing and gradient hardware has improved 
the once low-quality lung MR images caused by low water molecule density in lung tissue.  This 
study aimed to demonstrate pulmonary ventilation imaging in healthy controls and cystic fibrosis 
(CF) patients using 19F MRI to study ventilation kinetics.  19F MR images of twelve adult 
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subjects performing respiratory exercises were acquired using a Siemens TIM Trio 3 Tesla 
scanner following spirometry.   Ventilation kinetics within the lung space were computed by 
fitting dynamic 19F signal intensity values to a six-parameter fit model.  Statistical analysis of 
ventilation kinetic between groups revealed that CF lungs required significantly more time to fill 
and showed ventilation defects.  19F imaging presents an inexpensive method of quantitatively 
measuring lung function in both healthy and affected populations, creating the opportunity to test 
treatment efficacy of various pulmonary disease as well as structural and physiological lung 
measurements. 
Cell Tracking     One emerging application of 19F MRI is cell tracking using 
perfluorocarbon probes (PFC).  Human and murine cells were labeled with the PFC probe to 
explore feasibility of 19F MRI cell tracking and inflammatory response imaging in a CF cell 
model and murine Parkinson’s disease (PD) model.  Studies validated the uptake of the labeling 
agent by all cell types, showing minimal decrease in cell survival rates.  19F NMR and MRI 
techniques were employed to analyze loading efficiency and for cell quantification in vivo.  
We demonstrate preliminary imaging data of fluorine-19 gas and compounds suitable for 
pulmonary imaging and cell tracking. High signal to noise ratios are achievable with small 
animal imaging MR scanners as well as conventional 3T human systems with high bandwidth 
amplifiers.   
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CHAPTER ONE: INTRODUCTION 
Magnetic Resonance Imaging Principles 
The basic physical principles of nuclear magnetic resonance (NMR) form the foundation 
of magnetic resonance imaging (MRI).  Purcell et. al. [1] and Bloch et. al. [2] independently 
demonstrated the application of those principles to MRI in 1946 [1, 2].  Paul C. Lauterbur and 
Peter Mansfield shared the 2003 Nobel Prize in Physiology or Medicine due to their research in 
the 1970s relating to MRI.  Lauterbur discovered that additional magnetic field gradients could 
enable creation of crude two-dimensional (2D) images.  He was able to demonstrate that the 
extra gradients allowed him to create a cross-sectional image of water filled tubes, and that he 
was able to distinguish between the two types of water (ordinary and heavy) in each tube.  
Mansfield was able to better demonstrate resonance difference using gradients, and he 
discovered how to quickly analyze and transform signals into images.  The field of MRI 
technology has developed into a diverse and widely used tool for research and clinical 
applications. 
To facilitate discussion of MRI acquisition techniques for pulmonary imaging and cell 
tracking in this dissertation, the following will provide a brief review of the basic physical 
principles of NMR.  Readers can refer to “Magnetic Resonance Imaging: Physical Principles 
and Pulse Sequence Design” by Haacke et. al. [3] for further details on NMR and MRI physics 
and image construction. 
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Formation of MRI Signal 
The NMR signal originates from a property of many subatomic particles known as 
“spin”.  Only nuclei with an odd number of protons or neutrons exhibit spin angular momentum, 
J⃗. 
                                                                                        𝐽 = ℏ𝐼                                                              [1 − 1] 
J⃗ is represented as the product of the reduced Planck's constant, ћ and the intrinsic half-
integer spin, I.  The spinning of the nucleus, which has both charge and mass causes the nucleus 
to behave like a spinning charge, giving rise to a magnetic dipole moment, given by: 
                                                                                 𝜇 = 𝛾𝐽 = 𝛾ℏ𝐼                                                        [1 − 2] 
where γ represents the unique gyromagnetic ratio for each nucleus; gyromagnetic ratios for some 
NMR-sensitive nuclei are listed in Table 1. 1.  
Table 1. 1. NMR properties of select isotopes [3, 4]. 
Spins placed in an external magnetic field (B0) tend to align with that field, thus creating 
a net magnetization density that can be treated as a vector sum of the magnetic dipole moments 
(Figure 1. 1c) in a volume (M0).  Figure 1. 1d depicts a diagram of the bulk magnetization vector 
driven toward the positive z-direction.  In this schematic, a single proton is described as a 
spinning sphere with a mass and charge as well as an intrinsic spin, shown as a rotation of the 
nucleus about an axis (Figure 1. 1a).  The combination of the spin and charge causes the nucleus 
to exhibit magnetic properties not unlike a magnetic bar aligned with B0 (i.e. a dipole moment).  
 
Nucleus Spin 
Gyromagnetic 
ratio (MHz/T) 
Hydrogen (proton), 1H 1/2 42.577 
Helium-3, 3H 1/2 -32.44 
Oxygen-18, 17O 5/2 -5.77 
Fluorine-19, 19F 1/2 40.08 
Xenon-129, 129Xe 1/2 -11.86 
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The angular momentum caused by the spin “tips” the dipole moment way from its vertical 
alignment, causing it to precess or “wobble” about the vertical axis (Figure 1. 1b) at the 
precessional frequency known as the Larmor frequency (ω). 
The bulk magnetization vector can also be described by the differences in energy level 
within a population of dipole moments.  The potential energy of a single nucleus, PE can be 
expressed as a function of the angular moment for said nucleus and B0, or more specifically as a 
function of intrinsic spin, gyromagnetic ratio, and B0.  Half spin nuclei, such as 
1H or 19F, can 
either spin parallel or anti-parallel to the external magnetic field.  In other words, each dipole 
moment can have a spin value of I = ±1/2.  Spins aligned parallel to the magnetic field occupy a 
lower energy state, causing there to be slightly more spins aligned parallel to the magnetic field.  
Without the exposure to an external magnetic field, half-spin nuclei return to an even distribution 
Figure 1. 1. (a) A single nucleus depicted with a mass, 
charge, and spin that tends to align with the vertical 
external magnetic field, B0; (b) dipole moments are 
tilted away from B0 experience precession at a 
frequency of ω due to the angular momentum caused 
by the intrinsic spin; (c) a population of nuclei precess 
in synchrony in the presence of a uniform magnetic 
field, resulting in (d) a net magnetization density 
depicted as a vector, M0. 
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of parallel and anti-parallel alignment, eliminating the net polarization or magnetic effect.  At a 
clinical magnetic field strength of 3.0 T, the net polarization of hydrogen atoms at body 
temperature is about 9.9 x 10-6— this polarization though small still provides a detectible signal 
due to the high concentration of 1H nuclei in human and animal tissue.  The polarization yielded 
for fluorine-19 (19F) nuclei under the same conditions is nearly the same (9.3 x 10-6), however 
the concentration of fluorine atoms in human tissue is 4 μM versus 88 M for 1H nuclei.  
Therefore, it is essential to utilize exogenous fluorinated contrast agents to acquire a signal for 
19F MRI. 
MRI Signal Detection 
Precessing magnetization is detected through a pair of receiver coils tuned to the larmor 
frequency, which are typically aligned to the transverse (x-y) plane.  The transverse plane is 
defined as the plane perpendicular to the applied external field.  The transverse component of the 
time varying magnetic field is coupled with the receiver coils, inducing a signal that is 
proportional to the rate of change of the magnetization detected at the coil.  Because the two 
coils are positioned orthogonal to the x- and y-components of the transverse plane, the direction 
of rotation and angle of transverse magnetization are measurable over time. 
At equilibrium, net magnetization (M0) is parallel to the B0 field (along the z-axis), 
meaning there is no transverse plane magnetization component generating a signal.  NMR 
signals are generated by the application of a radio frequency (RF) pulse that applies a time-
varying magnetic field, B1 orthogonal to the main magnetic field, B0.  In other words, an RF 
pulse can be represented as a magnetic field vector of a set magnitude that rotates about the z-
axis on the x-y plane at the Larmor or excitation frequency.  It is essential that the B1 field rotates 
at the larmor frequency in order for the nuclei to be excited.  The nature of the rotating magnetic 
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field, B1 allows the ensemble of spins in the sample to progressively absorb energy and nutate 
away from the longitudinal axis (z-axis), creating the time-varying transverse component.  The 
angle of nutation or flip angle (α) depends on the magnitude of the RF pulse as well as the 
duration of its application to the sample.  Due to the complex nature of the bulk magnetization 
vector motion, the spin system can be depicted as in Figure 1. 2, with a special time-varying 
reference frame.  In this system, the frame of reference itself rotates about the z-axis at the 
Larmor frequency, making the depiction of complicated RF pulse excitation-relaxation motion 
possible.  After the RF pulse is applied, receiver coils measure the decay of the transverse 
magnetization component and the recovery of the longitudinal magnetization component. 
 
Figure 1. 2. The rotating magnetization field induces an oscillating signal at frequency ω as viewed in the (a) 
stationary frame and (b) rotating reference frame. 
Spin-Lattice and Spin-Spin Relaxation 
Spin-lattice relaxation describes the process by which the net magnetization returns to 
thermal equilibrium along the longitudinal axis.  This relaxation mechanism occurs when an 
individual nucleus attempts to reach a lower energy state (parallel alignment with B0 field) 
following an RF pulse.  Transitions from higher to lower energy states result in dissipation of 
energy (in the form of thermal motion) into the lattice of nearby atoms.  The thermal motion of 
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atoms creates time-dependent magnetic fields with frequencies close to ω.  This in turn allows 
energy state transition, which relaxes the sample back to thermal equilibrium.  Spin-lattice 
relaxation is characterized by the T1 relaxation time constant; it is defined as the time required to 
reach 63% of the equilibrium longitudinal magnetization.  
The transverse magnetization component is made up of the sum of the individual vectors 
from individual spins in the x-y plane during B1 field application.  Directly following the RF 
pulse, these individual spins begin their dephasing process, known as spin-spin relaxation.  This 
mechanism is caused by unavoidable changes in magnetic field spatial distribution due to the 
introduction of the tissues themselves into the magnetic field.  Interactions between proximal 
spins cause them to “speed up or down” due to their inherent magnetic property— magnetic 
susceptibility.  The difference in susceptibility of varying materials in a sample lead to subtle 
inhomogeneities in the field, which leads to dephasing.  In other words, the slightly 
heterogeneous magnetic field causes tissues at different locations to precess at slightly different 
Larmor frequencies. At high fields, susceptibility artifacts are exaggerated because variations in 
magnetic susceptibility is proportional to the magnetic field strength.  The end result is that the 
net magnetization eventually decreases. 
The transverse relaxation time constant, T2 characterizes spin-spin relaxation; it is caused 
by the inherent transverse dephasing due to the presence of nearby spins.  T2* incorporates 
perturbations in the B0 field which further decreases the transverse magnetization as well as the 
heterogeneous magnetic field caused by nearby spins; in other words, it takes into account both 
static and time-dependent effects.  T2* is typically much shorter than T2.  Unlike T1, T2 time-
varying changes occur at a much lower frequency range and are effected by variations in all three 
directions. 
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T1, T2, and T2* relaxation time constants are properties that are intrinsic to material.  It is 
the very difference in these properties that creates the contrast between material and tissues in 
MR images. 
Magnetic Field Gradients, Spatial Localization, and Image Formation 
Unlike other medical imaging modalities, the energy measured in MRI does not contain 
any intrinsic location information.  It is therefore necessary to employ other techniques (multiple 
gradients, Fourier transform, etc.) to provide geographical information.  In order to spatially 
localize received signals, known linear magnetic field gradients are applied in conjunction with 
the B0 field.  These gradients are applied in the x-, y-, and z-directions and can vary in 
application time, position, and gradient strength to create intentional magnetic field 
inhomogeneities. 
Slice selection is performed using a linear and non-RF magnetic field gradient applied in 
the z-direction during the RF excitation.  The Larmor frequency then becomes a function of 
location on the z-direction magnetic gradient (Gz).  Applying a band-limited RF excitation 
ensures that the received signal originates from a particular slab (or slice).  Frequency encoding 
employs a process similar to slice selection; a magnetic gradient is applied in a direction 
transverse to the z-direction.  This gradient is applied in such a way that its range fits into the 
bandwidth of that particular slice so that when readout occurs, there is additional spatial 
information within the slice.  Phase encoding occurs in the remaining direction (typically the 
shortest dimension) and usually occurs neither during RE excitation nor reception.  For phase 
encoding, the idea is not to change the frequency of the signals, but to allow for dephasing to 
occur linearly. 
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Because MRI signals detected by receiver coils are time-varying oscillations, they are 
best described as sinusoidal functions with unique amplitude, frequency, and phase.  Spatially 
encoded native MRI signals are obtained in the frequency domain, necessitating the use of 
inverse Fourier transforms to create an image in the spatial domain.  The k-space representation 
of an image depicts an object in the frequency domain; it is “filled” with the signal from receiver 
coils. 
 The filling of the k-space can vary by application, and the process is defined by the image 
sequence used.  Image pulse sequences in MRI refer to the pattern of application of RF pulses 
and gradients.  It is the variation in the RF pulse and gradient strength, frequency and duration 
that determine the location in space of an excitation, and therefore the resulting signal.  As such, 
the time-varying magnetic signal recorded is spatially encoded through time.  In other words, the 
k-space is a graphic representation of the area under the x- and y-gradients that are proportional 
to the spatial frequencies of those axes.  Inverse fourier transformations of the filled k-space 
allow the conversion of these special frequencies to spatial location. 
 While this provides a brief overview of the principles of conventional MR imaging, these 
principles also apply to multinuclear MRI.  In 19F MRI, exogenous fluorinated contrast agents 
are introduced to biological tissue.  Coils specially tuned to the 19F isotope are a relatively 
inexpensive and simple to construct, allowing current clinical scanners to be used in 19F MRI 
applications.  In essence, implementation of 19F MRI techniques is relatively easy to achieve 
through improved image pulse sequence and dual-tuned coil hardware. 
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CHAPTER TWO: FLUORINE-19 MAGNETIC RESONANCE IMAGING 
OF PULMONARY VENTILATION IN CYSTIC FIBROSIS PATIENTS 
 Introduction 
Cystic Fibrosis (CF), is an autosomal recessive genetic disease affecting multiple tubular 
organ systems, which commonly causes persistent pulmonary infections and severely decreases 
lung function [1].  Pulmonary failure, in conjunction with complications in the liver, pancreas 
and intestines characterize this disease—the most common life-limiting heritable disease 
amongst Caucasians [2, 3].  Caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene [1-2, 4], patients with CF inherit two sets of mutated CFTR 
genes—one from each parent [1, 2].  The genetic defects of CFTR genes mainly prevent proper 
transport of chloride and bicarbonate ions.   It is believed that the interaction between defective 
CFTR ion channels and epithelial sodium channels causes airway dehydration, disrupting 
mucociliary clearance [4].  This provides an ideal environment for bacterial growth in the lungs, 
prevents nutrient uptake due to pancreatic damage, and leads to a host of problems caused by 
electrolyte imbalances in the patient [1-3].  The chronic infection and inflammation of the 
pulmonary system contribute to the obstruction of airways, leading to bronchiectasis and 
irreversible lung damage [1].  Measuring and recording inflammatory damage to airways caused 
by defective mucus clearance is of prime importance in CF research. 
There is an increasing need in CF research to develop methods of acquiring physiological 
information as well as anatomical data of the lungs for treatment efficacy assessment and early 
lung disease detection.  Current gold standards of functional pulmonary assessment include 
pulmonary function tests (PFTs), lung computed tomography (CT) for anatomical image 
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acquisition and scintigraphy to obtain measurements of pulmonary function, i.e. ventilation-
perfusion (V/Q) scans [5-8].  Clinically, spirometry measurements (forced expiratory volume in 
one second; FEV1)—a type of PFT—is widely used to predict outcomes in moderate to severe 
CF patients [5, 9, 10].  Spirometry measurements are limited however, by their lack of local 
functional information, which is crucial in heterogenous diseases such as cystic fibrosis.  
Conventional pulmonary imaging techniques have the advantage of providing morphological and 
some functional data [6-8], but are limited by patient exposure to ionizing radiation. 
Unlike the current methods of pulmonary imaging, MRI-based methods are not limited to 
static global measurements, thus allowing the investigation of regional physiological and 
pathological changes over a period of time [12, 13].  Furthermore, MRI-based techniques present 
a noninvasive method of quantitatively measuring pulmonary function without exposing subjects 
to ionizing radiation while increasing image acquisition speed.   Because traditional MRI 
techniques detect their signal from hydrogen-1 (1H) protons, low water-molecule density and 
high susceptibility in the lungs results in low-quality pulmonary images.  With the advancement 
of multi-nuclear hardware and better pulse sequences, the use of exogenous gases as a contrast 
agent has greatly improved the suitability of MRI techniques for pulmonary imaging.  
Hyperpolarized gases, such as helium-3 (3He) and xenon-129 (129Xe) are promising choices for 
an exogenous gas, mainly because of their relatively high signal-to-noise ratio (SNR) [11].  
Fluorinated gases– unlike hyperpolarized gases– do not require a polarizing device, thus 
reducing costs and can be mixed with oxygen [14].   Compounds containing fluorine-19 (19F) are 
particularly attractive as a contrast agent not only because they are inert and non-toxic, but also 
because the infinitesimal intrinsic 19F signal occurring biologically does not hinder ventilation 
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measurements [15].   This study focuses on the use of a 19F exogenous gas, perfluoropropane (C3-
F8; PFP) to enhance pulmonary image acquisition through 
19F magnetic resonance imaging (19F 
MRI).  PFP is an ideal 19F contrast agent because of low absorption rate by tissue due to low 
water solubility, and its relatively low spin-lattice relaxation time (T1; 12.4 ms), which aids rapid 
image acquisition [16].  
Previous studies have demonstrated the safety and efficacy of PFP (79%) with oxygen 
(21%) as a contrast agent in 19F MRI in healthy subjects, chronic obstructive pulmonary disease 
(COPD) patients, asthma patients and lung transplant recipients [15, 16].  In this study, the 
regional ventilation kinetics and ventilation defect identification is explored in healthy subjects 
and those with cystic fibrosis.  The goal of this study was to gather regional pulmonary 
ventilation information by means of multiple-breath 19F MRI acquisitions with sufficient 19F 
signal strength and image contrast. 
Methods 
The University of North Carolina Institutional Review Board approved this study.  
Following informed consent by the subjects, 6 healthy volunteers and 8 cystic fibrosis patients 
(FEV1>30%) received a clinical assessment and spirometry.  
19F MRI scans were then performed 
to obtain images of the gas wash-in and wash-out. 
Spirometry 
A trained technician performed spirometry measurements with a KoKo spirometer 
(NSpire Health, Longmont, CO) following the American Thoracic Society guidelines for 
spirometry performance and interpretation [17]. 
19F and 1H MRI procedures 
All 1H and 19F MRI were acquired using a Siemens TIM Trio 3 Tesla MRI scanner 
(Siemens Healthcare, Erlangen, Germany) with multinuclear capabilities.  Anatomical 1H MR 
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images for lung mask generation were acquired using a 2D coronal echo-planar fast spin echo 
sequence (HASTE) with subjects laying feet-first supine (1.3125 mm x 1.3125 mm pixels, 6 mm 
slice thickness, 1500 ms repetition time, 102 ms echo time, 320 x 320 x 30 acquisition matrix, 
150˚ flip angle, 488 Hz/pixel bandwidth).   
19F MR images were performed using a custom-made 8-channel 19F-tuned chest coil 
(ScanMed, Inc., Omaha, NE) tuned to the 19F frequency.  3D coronal gradient echo images (6.25 
mm x 6.25 mm pixels, 15 mm slice thickness, 13 ms TR, 1.63 ms TE, 64 x 64 x 18 acquisition 
matrix, 90˚ FA, 130 Hz/pixel bandwidth) were obtained while subjects breathed the exogenous 
contrast medical grade gas, PFP (79% PFP, 21% O2; Air Liquide Healthcare, Plumsteadville, 
PA).  Subjects were fitted with a facemask with a non-rebreathing valve that allowed the inhaled 
gas source to be easily switched between room air and PFP.  Subjects were instructed through 
the breathing cycle; a cycle consisted of two inhaled tidal breaths followed by a full inspiration 
and a 15-second breath-hold, during which the 19F MRI was acquired.  An initial cycle with 
room air was completed to set the baseline signal followed by five breathing cycles with the PFP 
gas to capture 19F wash-in ventilation. An additional set of at least five cycles (wash-out) were 
performed until the 19F signal from the gas was no longer present. 
Safety Assessments 
Gas flow to the subjects’ breathing masks was monitored using an MR-compatible 
pneumotachometer (BIOPAC Systems, Inc., Goleta, CA).  A finger pulse oximetry system 
(Model 7500FO; Nonin Medical Inc., Plymouth, MN) acquired heart rate and oxygen saturation 
levels.  To ensure subject safety, outputting Douglas bags were equipped with gas-empty sensors 
that when triggered, switched the gas supply to room air.  Transducer amplifier modules (Model 
DA 100C; BIOPAC Systems, Inc., Goleta, CA) amplified signals obtained by the pneumotach 
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transducers.  All sampled signals were recorded, digitized and displayed to a PC through a pair 
of digitizing acquisition modules (Model DI-149; DataQ Instruments, Akron, OH). Windaq 
(DataQ Instruments, Akron, OH) and Oxigraf (Oxigraf Inc., Mountain View, CA) software 
allowed for the digital archiving and real-time display of all signals.   Exhaled CO2 and O2 levels 
were recorded utilizing an oxygen gas analyzer (Oxigraf O2Cao; Oxigraf Inc., Mountain View, 
CA).   To confirm that PFP inhalation did not change the lung function of volunteers, spirometry 
measurements were performed prior to each scan and directly following the imaging session.  
Image Post-Processing 
The anatomical 1H MRI and functional 19F MRI datasets were post processed using 
MIMVista (MIM Software, Cleveland, OH) and MATLAB (Mathworks, Inc., Natick, MA).  1H 
images were aligned to the 19F image dataset by means of automatic non-rigid registration 
transforms.  A semi-automatic region-growing algorithm was used to create lung masks based 
off of the 19F and conventional 1H MRI datasets.  Lung masks were utilized to remove 
background noise outside of the lung field of view (FOV).   
Ventilation kinetics within the lung FOV were computed in MATLAB by fitting 19F 
signal intensity values to a previously described six-parameter fit model  through a Levenberg-
Marquardt algorithm[18].  A time series of signal intensity per voxel was created from the 
temporal compilation of wash-in and wash-out functional 19F MRI datasets.  For a single voxel, 
the series of signal intensity values over time were fitted to the exponential ventilation wash-
in/wash-out model.  The model (Equation 1) fits the following parameters: wash-in rate constant 
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(τ1), wash-out rate constant (τ2), baseline signal intensity (D0), equilibrium of 19F signal intensity 
(Df), starting point of the wash-in segment (t0), and starting point of wash-out segment (t1). 
 
Equation 2. 1.  The exponential model equation used to characterize ventilation kinetics from the 19F MRI datasets. 
Time-to-steady-state (TSS) of 19F signal was defined as the time required to maximum 
saturation of PFP gas in each voxel as determined from temporally and spatially registered 19F 
MR images.  A TSS map was produced by finding the difference between t1 and t0 on a voxel by 
voxel basis. 
Ventilation defect volume (VDV) was defined as the volume within the lung field of 
view (as defined by the conventional 1H anatomical MRI) that was not ventilated by the PFP gas, 
and therefore did not produce a detectable 19F signal (sum of mean signal intensity of 
background noise and two times the standard deviation; SD).  VDV was expressed as the ratio of 
thoracic volume calculated from 19F MR images at maximum wash-in to total thoracic volume 
measured from the morphological 1H MRI. 
Each parameter was characterized in terms of estimates of the mean and the standard 
deviation (SD), with 95% confidence intervals within the lung FOV.  Lung function data was 
compared via Students’ T test. 
Results 
Six healthy control and eight cystic fibrosis volunteers participated and completed study 
procedures.  Subject characteristics are summarized in Table 1.  Data from two subjects were 
excluded: technical error during the scans resulted in unusable data for the first subject, and a 
𝐷 𝑡 = 𝐷0 +  𝐷𝑓 − 𝐷0  1 − 𝑒
− 𝑡−𝑡0 
𝜏1  , 𝑡0 ≤ 𝑡 ≤ 𝑡1 
                = 𝐷0 +  𝐷𝑓 − 𝐷0  1 − 𝑒
− 𝑡1−𝑡0 
𝜏2  𝑒
−(𝑡−𝑡1)
𝜏2 , 𝑡1 ≥ 𝑡 
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second data set was excluded from a subject whose beard caused significant gas leakage from the 
mask.  Oxygen saturation remained above 90% in all subjects for the duration of the imaging 
study, and no adverse effects were observed with the exception of a transient change in voice 
pitch in two subjects—one healthy control and one CF subject—lasting less than a half-hour 
after the final PFP gas inhalation. 
Table 2. 1. Subject Characteristics 
 
Parameter Healthy Cystic Fibrosis 
Number of Subjects 
    Female (male) 
6 
5 (1) 
6 
3 (3) 
Age 
    Mean ± SD 
    Range 
 
26.7 ± 5.0 
21-36 
 
33.3 ± 15.1 
22-65 
Minimum O2 Levels, % 
    Mean ± SD Mean 
 
96.2 ± 2.5 
 
96.5 ± 1.8 
Maximum Heart Rate, bpm 
    Mean ± SD 
 
76.8 ± 12.7 
 
89 ± 19.6 
FEV1 Percent Predicted, % 
    Mean ± SD 
    Range 
 
 
105 ± 11 
89-126 
 
64 ± 24 
37-105 
FEV1 Percent Predicted post-
imaging, % 
    Mean ± SD 
    Range 
 
105 ± 12 
90-129 
 
64 ± 23 
40-102 
 
Healthy controls had a mean FEV1 percent predicted of 105% ± 11% (range 89%-126%), 
while CF subjects had a mean FEV1 percent predicted of 64% ± 24% (range 37%-105%).  Post-
imaging session spirometry measurements showed no change in mean FEV1 measurements in 
either the healthy control or CF groups following PFP gas inhalation. 
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Figure 2. 1. A coronal panel (anterior to posterior: left to right, top to bottom) of the morphological 1H HASTE MRI 
of a healthy control subject. 
In all, 12 complete image datasets were produced; each subject had anatomical 1H MR 
images and functional 19F MR image sets.  Figure 1 displays a typical morphological 1H MRI 
from a healthy control; registration of the anatomical proton MRI with the functional 19F MRI 
datasets (Figure 3) aided in the creation of lung masks.  Lung masks allowed for the alignment of 
lung airspace between the anatomic and functional image sets.  A series of coronal 19F MRIs 
(Figure 2) show the PFP gas airway ventilation in healthy and CF volunteers.  Homogeneous 
PFP airway ventilation was noted in healthy participants, whereas CF subjects—especially those 
with lower lung function—displayed heterogeneous ventilation.  Ventilation defects were also 
observed in subjects with severe obstruction—in fact, some airway compartments failed to 
demonstrate any 19F signal from the PFP gas in spite of the multiple breath protocol. 
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Figure 2. 2. Coronal images of 19F MRI scans in a representative normal (top panel) and CF lung with severe 
obstruction (bottom panel) at end of PFP gas wash-in.  Severe obstruction in the CF subject lead to heterogeneous 
airway ventilation as compared to the healthy control. 
 
Figure 2. 3. Here, an anatomical HASTE 1H MRI is overlaid with the functional 19F MRI dataset (rendered in “hot 
iron” color scale) to depict the airspace of a healthy control.  Registration of the anatomical and functional image 
sets was completed to assist in the creation of lung masks. 
The aligned 19F MRI time series were used to produce heat maps for each of the six 
ventilation fit parameters, wherein a single voxel of a parameter map represented the fit 
parameter value of the corresponding voxel on the anatomical image set.  TSS maps for healthy 
control (FEV1: 3.1 L, 103% predicted) and CF subject with severe disease (FEV1: 1.01L, 37% 
predicted) are shown in Figure 4.  From this figure, the prolonged time to achieve signal 
equilibrium in the CF lung. 
19 
 
 
Figure 2. 4. Color-mapped images represent the time required to achieve a steady state of PFP signal in each lung 
voxel for a normal (top panel) and CF subject (bottom panel). Brighter voxels indicate a longer time to achieve 
equilibrium of gas wash-in. 
Overall, CF lungs required significantly more time to fill; mean TSS was 324.1 ± 45 
seconds and 226.4 ± 33.1 seconds for CF subjects and healthy controls, respectively (p = 
0.0021).  CF lungs also saw a more heterogeneous filling process, with a skew of -1.8 versus the 
normal skew of 1.3.  Histograms displaying the distribution of individual TSS values throughout 
the lung airspace were plotted (Figure 5).  A threshold TSS value was determined using data 
from healthy subjects (n=5).  The TSS threshold—defined as the sum of the mean of normal TSS 
values and two SD from the first five normal subjects—was used to classify slow-filling 
compartments.  For CF subjects, 19% ± 22% of the lung volume was defined as slow-filling, 
whereas only 2% ± 2% of the lung airspace was classified as such in healthy subjects 
(Satterthwaite t-test p-value = 0.08). 
 
Figure 2. 5. The distribution of voxel TSS values (normalized to total lung voxels) in healthy (left panel) and CF (right 
panel) subjects. 
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Discussion 
 Traditionally, the use of MRI techniques to accomplish pulmonary imaging has been far 
surpassed by the use of MRI on other organs.  Recent efforts to develop pulmonary MRI 
methodologies must overcome intrinsic disadvantages found in the lungs.  One such 
disadvantage is the very short effective transverse relaxation time (T2
*)  found in the lungs.  This 
is caused by magnetic field inhomogeneity created by the difference in diamagnetic 
susceptibility between water in the lungs and air [19].  Low proton density as well as respiratory 
and cardiac motion artifacts further impede MRI of the lungs [19-21].   
Ultra-short echo time (UTE) MRI, described as pulse sequences with echo times (TE) 10-
200 times shorter than those conventionally used [22], was developed to combat issues arising 
from short T2
* times [22, 23].  Pathophysiological anatomic variations (bronchiectasis, airway 
wall thickening, etc.) in young children with CF have successfully been captured with UTE MRI 
[24].  While shown to correlate well with HRCT in the depiction of anatomical features [23, 24], 
UTE MRI does not provide functional information such as airway ventilation or perfusion.   
 Oxygen-enhanced (OE) MRI capitalizes on the shortening of longitudinal relaxation 
times (T1) in blood, plasma, and tissue in the lungs due to the slightly paramagnetic nature of 
oxygen [25].  OE MRI involves the inhalation of hyperoxic mixtures of medical-grade oxygen 
(≥40%) during imaging procedures, inherent ventilation and perfusion weighting can then be 
quantified with parametric maps from the resulting images [25].   Because the kinetics of oxygen 
transfer can be represented as the magnitude and rate of T1 changes [25], OE T1 mapping has 
been successfully used to depict lung function.  Oxygen-enhanced T1 mapping of lungs in 
patients with COPD showed that abnormal T1 times positively correlated with perfusion 
abnormalities [26].  Overall studies indicate that OE MRI correlates well with spirometry 
measurements, diffusion capacity, and hyperpolarized gas MRI in the detection of ventilation 
21 
 
defects [27].  Notwithstanding, OE MRI abnormalities found in CF patients is likely indirect due 
to the fact that these abnormalities likely arise from poor gas diffusion [28]. 
Interest in utilizing hyperpolarized gas MRI has grown in recent years [29-35] as it 
allows for the depiction of ventilation abnormalities caused by various airway diseases.  The 
necessity of onsite polarizing devices greatly limits gas availability and leads to high costs, 
furthermore research shows conflicting results regarding the correlation of HP 3He MRI 
ventilation defects to PFTs [32-35].  Performing quantitative ventilation with HP MRI 
methodologies are further limited by presence of oxygen, which reduces the signal from the 
hyperpolarized gases [36].   
This study explored the early feasibility of performing 19F MRI in stable CF patients with 
mild, moderate, and severe lung disease.  No adverse effects were observed and sufficient signal 
was detected in all subjects regardless of disease symptom severity.  The data collected from 
subjects was used to represent ventilation kinetics by modeling the dynamic gas data.  Results 
from this study suggest that patients with CF have VDV reflected in their 19F MRI datasets, and 
require significantly increased times to reach 19F gas ventilation equilibrium than healthy 
controls.  Further studies would be required, however, to ascertain the efficacy of this method in 
the detection of mild lung disease as compared to other outcome measures.  Current data 
presented in this study is limited by poor understanding of the test-retest variability of 19F MRI in 
CF patients.  However, 19F MRI research by Charles et al of asthma patients suggests reasonable 
short-term repeatability [37].  However, the day-to-day changes in mucus plugging and gas 
trapping seen in patients with moderate to severe CF could potentially present high retest 
variability.  Notwithstanding, this technique could be invaluable in applications outside of CF.  
19F MRI has already been investigated for other lung disease applications (COPD and asthma) 
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[13, 15] and it could be useful in other applications such as post-lung transplant surveillance, 
longitudinal growth in survivors of neonatal respiratory distress.  Furthermore, 19F MRI has the 
potential to replace low does CT in pediatric CF patients. 
The current measure of lung function in this study (TSS) is somewhat limited in the 
information that it provides.  The time required to reach maximum signal places an emphasis on 
mucosal obstruction and poorly characterizes other pathophysiological features such as 
bronchiectasis.  As an alternative, the wash-in and wash-out rate constants would better 
characterize these features. 
Conclusion 
F-19 imaging presents a unique opportunity to explore and reduce the heterogeneity of 
lung function and evaluate treatment response in affected populations without exposing patients 
to ionizing radiation.  Widespread availability of 3T MRI scanners and the commercially 
available PFP gas makes this technique a relatively feasible option for many academic centers.   
Unlike other methods of pulmonary imaging (HRCT, UTE MRI, etc.), registration of 
conventional HASTE sequences with functional 19F MRI datasets allows for the spatial 
correlation of structural and functional features for each subject.  In the future, ventilation 
modeling techniques will need to be improved for the incorporation of the wash-in/out rate 
constants that better represent physiological differences between groups.  In addition, further 
validation of this technique by correlating 19F MRI ventilation kinetics to other functional 
imaging modalities will be necessary.  19F MRI imaging presents a relatively inexpensive, 
radiation-free method of quantitatively assessing lung function in both healthy and CF 
populations, creating the potential of an alternative outcome measure for CF clinical trials. 
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CHAPTER THREE: FLUORINE-19 MAGNETIC RESONANCE IMAGING 
FOR CELL TRACKING AND INFLAMMATION IMAGING  
Introduction 
Cellular-based therapy is a key component in the treatment of a variety of complex 
medical conditions that require development of noninvasive methods to observe cell behavior 
and movement within animal and human subjects [1, 2].  Improved understanding of cell bio-
distribution also provides information on the development and treatment of many critical 
diseases, and subsequently their inflammatory responses [1].  One emerging application of 
fluorine-19 (19F) MRI is cell tracking using perfluorocarbon (PFC) probes, a biologically and 
chemically inert molecule containing 19F nuclei. 
A hallmark of airway disease research has long been the investigation of potential 
treatment using gene or stem cell therapy [3-7].  Diseases like cystic fibrosis (CF) are 
characterized by deficient ion transport in columnar epithelial cells, which has a significant 
clinical impact on the pulmonary system [8].  Consequently, restoration of airway epithelia to 
address resulting complications (ex. poor mucus clearance, chronic bacterial infection, and 
inflammation) is of great interest to the CF research community.  To address this need, 
researchers have explored gene and cell therapy as a means to restore function in airway 
epithelial cells, with varying results [7, 9-11].  In vitro gene therapy studies have shown that 
even a small percentage of the CF cultured epithelial cells treated with normal CFTR gene 
vectors can produce healthy phenotypic function [12].  Conversely, localization of therapeutic 
cells—which are often blood cord- or marrow-derived—to sites of injury in the lungs is not well 
understood [12].  Current methods used to confirm delivery of stem cells to injured lung tissue 
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include fluorescence imaging and immuno-histochemical phenotyping [3, 13], both of which are 
not ideal for animal model studies or clinical trials.  19F MRI cell tracking techniques can be 
employed to provide in vivo evidence and quantification of therapeutic stem cells to sites of lung 
injury in CF models.  
Disease models of central nervous system (CNS) disorders such as Alzheimer’s disease 
(AD) or Parkinson’s disease (PD) are indispensable tools in the search for novel therapies.  
Recent studies have explored the delivery of therapeutics across the blood-brain barrier (BBB) 
[14-16]—a major impediment of drug delivery for neurodegenerative disease treatment—to stop 
and even reverse disease progression in murine models [14, 15].  In contrast, previous PD and 
AD treatments have focused on providing symptomatic relief at the expense of adverse side 
effects and patient drug resistance development [17].  Consequently, novel therapies whereby 
drug-loaded macrophages hone to sites of inflammation in the brain for targeted drug delivery 
are being explored.  Immunocytes like macrophages exhibit diapedesis and chemotaxis 
processes, which give them an intrinsic homing property of migration to sites of inflammation 
[18].  Studies have capitalized on this homing property to deliver glial cell-derived neuronal 
growth factor (GDNF) to produce neuroprotection and reverse the progression in PD mouse 
models [14].  Though initial investigations of macrophage-mediated drug delivery have shown 
promising results [14-16], the mechanisms are not fully understood.  There is some concern that 
macrophage loading techniques or inflammation sites aside from CNS inflammation can impact 
trafficking to the brain [15].  It is therefore necessary to have a means to display and analyze the 
biodistribution and pharmacokinetics of macrophages in murine models of neurodegenerative 
disorders. 
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Cell labeling using PFC probes in conjunction with F-19 MR imaging techniques allows 
for the visualization of cellular trafficking patterns.  Furthermore, inflammation and the 
inflammatory response, which is associated with cellular trafficking can also be visualized and 
potentially quantified.  Due to the innocuous nature (even at high doses) of PFC probes, 19F MR 
cell tracking has utility in providing in vivo information through non-invasive means for various 
disease models.     
Cytotoxicity and loading efficiency studies were conducted on human bronchial epithelial 
(HBE) progenitor cells— a potential option for future clinical CF cell therapy investigations— 
and a macrophage-like human monocytic THP-1 cell line.  These experiments established 
labeling procedures and 19F MRI cell tracking capabilities for future in vivo applications.  Cell 
tracking of inflammatory cells was also conducted on a Parkinson’s disease mouse model using 
19F MRI techniques.  F-19 MRI of PFC-labeled murine macrophages was conducted in vivo 
following toxicity and PFC loading efficiency studies of the macrophages.  These studies aim to 
provide a proof-of-concept for the use of 19F MRI cell tracking techniques to depict and quantify 
the in vivo trafficking and biodistribution of PFC-labeled cells in murine models of cystic 
fibrosis and Parkinson’s disease. 
Methods 
Cystic Fibrosis Model Cell Culture Procedures  
Experiments were performed using HBE stem cells, harvested from the excised lung 
tissue of healthy adults (n=3) and purchased macrophage-like human monocytic THP-1 cell line 
(ATCC TIB-202; American Tissue Culture Collection, Manassas, VA) previously described [19, 
20]. 
HBE progenitor cells were cocultured with irradiated fibroblasts to create conditionally 
reprogramed cell (CRC) which conditionally induce cell proliferation. 
30 
 
Irradiated 3T3-J2 mouse fibroblasts were cultured at 37˚C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/mL 
penicillin, 100 μg/mL streptomycin, and 100 μg/mL glutamine (complete DMEM; Gibco, 
Gaithersburg, MD).  After allowing 3T3 J2 murine fibroblasts feeders to attach for 24 hours, 
CRC cultures were co-seeded on a feeder layer in F +Y medium and passaged every 3-5 days.  
At 80% confluence, feeders were removed via brief Accutase (STEMCELL Technologies, Inc., 
Vancouver, Canada) incubation and gentle agitation to prepare HBEs for further use in 
experiments. 
Human monocytic THP-1 cells were cultured in RPMI-1640 media (RPMI Media 1640; 
Gibco, Gaithersburg, MD) containing 10% fetal bovine serum (FBS), 1.4 mmol/L L-glutamine 
(Gibco, Gaithersburg, MD), 50 μg/mL penicillin, 50 μg/mL streptomycin, and 100 μg/mL 
neomycin (Gibco, Gaithersburg, MD) at 37˚C and 5% CO2.  THP-1 cells were differentiated 
from monocytes to macrophages by incubation in 200 nM phorbol 12-myristate 13-acetate 
(PMA; Sigma, St. Louis, MO) for a period of 72 hours. 
Parkinson’s Disease Model Cell Culture Procedures 
Macrophages extracted from the bone marrow of mice were obtained from the femurs of 
C57/BL male mice as previously described [21].  Cells were cultured for 12-14 day in DMEM 
(DMEM; Invitrogen, Carlsbad, CA) medium supplemented with 100 U/mL macrophage colony-
stimulating factor (MCSF).  Murine macrophages were labeled with Cell Sense at concentrations 
of 0 mg/mL (unlabeled negative control), 0.75 mg/mL, or 1.5 mg/mL for 4- or 24- hour periods. 
Animals 
  A Parkinson’s disease mouse model was created by inducing inflammation of the 
striatum (SN) in two C57BL/6 mice using a 1μL lipopolysaccharide (LPS) injection.  Bone 
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marrow-derived macrophages (BMM) labeled at a concentration of 1.5 mg/mL of Cell Sense for 
24 hours were introduced 24 hours after LPS injections through intravenous (IV; 2x106 cells) or 
intraventricular (Ivt; 2x105 cells) injections.   
This study was performed in accordance with the recommendations of Principles of 
Animal Care outlined by the National Institutes of Health and approved by the Institutional 
Animal Care and Use Committee of the University of North Carolina at Chapel Hill.  Surgeries 
were performed under sodium pentobarbital anesthesia to minimize animal suffering.  All 
manipulations were carried out under a sterilized laminar hood, and food and water were given 
ad libitum.  Mice were anesthetized with 1% isoflurane gas for the duration of imaging 
procedures. 
Cytotoxicity and Fluorescence Measurements 
Following removal of feeders, CRC-grown HBE cultures were seeded onto a collagen 
coated black, flat glass bottom 96-well plate (Corning Inc., Durham, NC) at a density of 104 cells 
per well (n=3).  CRC-grown HBEs were incubated at 37˚C and 5% CO2 in F+Y media for 24 
hours to maximize adherence.  THP-1 cells and murine macrophages were also seeded onto a 
collagen coated black, flat glass bottom 96-well plate at a density of 104 cells per well and 
differentiated as described above.  All cell types were washed with PBS and labeled with a dual 
19F MRI and fluorescence imaging agent, Cell Sense (CS-ATM DM Red, Celsense, Inc., 
Pittsburgh, PA).  Cell Sense is a perfluoropolyether (PFPE) nanoemulsion with a total fluorine 
content of 120 mg/mL designed to facilitate cellular uptake across all cell types.  Labeling was 
achieved by incubating cells for 24- and 48-hour periods in their respective media containing 
either 0 mg/mL (negative control), 1.5 mg/mL, 3.0 mg/mL, 6.0 mg/mL or 12.0 mg/mL Cell 
Sense for the HBEs and THP-1 macrophage-like cells.  Murine C12 macrophages were 
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incubated for 4- and 24-hour periods in media containing either 0 mg/mL, 0.75 mg/mL, or 1.5 
mg/mL Cell Sense. 
Cells were washed three times with PBS following incubation in Cell Sense and 100 μL 
of their respective media was added to each well for fluorescence imaging, quantitative 
fluorescence measurements and a cytotoxicity assay.  Plates were loaded into an Infinite M1000 
plate reader (TECAN, Männedorf, Switzerland).  Fluorescence was measured with an excitation 
and emission wavelength of 595 nm and 610 nm, respectively.  Cytotoxicity was evaluated via a 
water-soluble tetrazolium salt assay (WST-1 Cell Proliferation Assay System; Takara Bio Inc., 
Shiga, Japan) according to the manufacturer protocol.  Absorbance was measured using a 
Cytation 5 (Biotek, Winooski, VT, USA) cell imaging multi-mode reader at an emission 
wavelength of 440 nm. 
NMR Spectroscopy 
Cultured cells were labeled with Cell Sense and incubated in standard conditions for 24 
hours at concentrations of 0 mg/mL, 1.5 mg/mL or 3.0 mg/mL.  Cells were washed three times 
with PBS and pelleted via centrifugation for NMR experiments. 
One-dimensional 19F NMR spectra were recorded with a Varian Inova 500 MHz 
spectrometer (UNC Eshelman School of Pharmacy NMR Facility, Chapel Hill, NC) at ambient 
temperature with reference to trifluoroacetic acid (TFA; Aldrich Chemical Co., Milwaukee, WI) 
and deuterium oxide (D20; Aldrich Chemical Co., Milwaukee, WI) as the solvent.  Data was 
analyzed using the Varian built-in software, VNMR (VNMR Version 6.1; Varian, Inc., Palo 
Alto, CA). 
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MR and Fluorescence Imaging 
Fluorescence imaging was 
performed on an Olympus IX-81 inverted 
wide-field microscope (Hooker Imaging 
Core, UNC, Chapel Hill, NC).  
Conventional 1H MRI and 19F MRI were 
acquired on a horizontal 9.4 Tesla Bruker 
Biospec Small Animal Scanner (UNC 
Small Animal Imaging Core, Chapel Hill, 
NC).  The MRI scanner was equipped with 
a custom-made dual-tuned 1H/19F surface 
coil with a 2.5 cm diameter.  19F MR 
images were acquired using two-
dimensional rapid acquisition with 
relaxation enhanced (2D RARE) sequence 
with a RARE factor of 32, repetition time 
(TR) = 1000 ms, echo time (TE) = 8.765 
ms, 3000 signal averages, a 10kHz 
bandwidth, field-of-view (FOV) of 3.2 cm 
x 3.2 cm and an image matrix size of 32 x 
32.  Reference phantoms with a known 
quantity of F atoms was situated within the 
FOV for cell quantification purposes (300 
μL 0.75 Cell Sense and 300 μL 1.5 Cell 
Figure 3. 1. Fluorescence images of labeled THP-1 cells 
(left) and CRC-grown HBEs (right) taken following a 24-
hour incubation period in media containing shown Cell 
Sense concentrations. 
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Sense).  HBE progenitor cells labeled in 3.0 mg/mL Cell Sense for 24 hours were used to prepare 
cell phantoms with 1 x 106 and 4 x 106 cells, respectively. 
Results 
Cystic Fibrosis Model Results 
Both the HBEs and macrophage-like THP-1 cells were loaded with the PFC probe, Cell 
Sense.  Inverted microscope images of both cell types treated with varying labeling 
concentrations of Cell Sense were captured following a 24-hour incubation period.  Images 
(Figure 3. 1) show increasing fluorescence with increasing concentrations of Cell Sense in the 
incubation media.   
The increase in fluorescence with PFC probe concentration is also reflected in TECAN 
plate reader measurements (Figure 3. 2).  While an ANOVA test revealed that the difference in 
mean fluorescence was statistically significant (p<0.05) between labeling conditions for both cell 
types, pairwise t-tests indicated that only THP-1 cells incubated at a Cell Sense concentration of 
12.0 mg/mL fluoresced more than THP-1 cells incubated at lower concentrations.  For HBEs 
however, pairwise t-tests showed that the difference in fluorescence was statistically significant 
between all concentration levels with the exception of one; the difference in fluorescence was not 
statistically significant between cells incubated at 1.5 mg/mL and 3.0 mg/mL (Table 3. 1).  In 
essence, higher labeling concentrations resulted in increased Cell Sense uptake, but not always 
significantly so.   
  
35 
 
 
Figure 3. 4. Mean plate reader fluorescence measurements for THP-1 macrophage-like cells and HBE cells post 24-
hour incubation in vary concentrations of Cell Sense. 
Table 3. 1 Pairwise t-test p-values of fluorescence between labeling conditions for THP-1 and HBE cells. P-values 
greater than 0.05 indicates a statistically insignificant difference in fluorescence between the two Cell Sense labeling 
concentrations. 
 
   
Cell Type 
Cell Sense 
Concentration 
1.5 
mg/mL 
3.0 mg/mL 6.0 mg/mL 12.0 mg/mL 
THP-1 
macrophage
-like 
 
0 mg/mL p > 0.05 p > 0.05 p > 0.05 p = 3.2e-7 
1.5 mg/mL - p > 0.05 p > 0.05 p = 4.0e-7 
3.0 mg/mL - - p > 0.05 p = 7.5e-7 
6.0 mg/mL - - - p = 4.6e-6 
CRC-grown 
HBE 
0 mg/mL p = 2.7e-9 p = 4.3e-12 p < 2e-16 p < 2e-16 
1.5 mg/mL - p > 0.05 p = 2.9e-8 p < 2e-16 
3.0 mg/mL - - p = 3.2e-5 p = 1.2e-15 
6.0 mg/mL - - - p = 3.6e-9 
 
WST-1 assay toxicity experiments showed little difference in cell viability based on 
concentration of Cell Sense present in incubation media; ANOVA tests revealed that differences 
between labeling conditions were not statistically significant for either cell type (p > 0.05).  As 
compared to negative controls (unlabeled cells), PFPE-labeled cells exhibited at least 80% 
survival (Figure 3. 3). 
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Figure 3. 5.WST-1 assay toxicity studies demonstrated that incubation of cell in the labeling agent had little impact 
on survivability. 
NMR studies were performed on THP-1 macrophage-like and HBE cell pellets (n=3 for 
each cell type and labeling concentration) incubated in media containing 1.5 mg/mL and 3.0 
mg/mL Cell Sense for 24 hours (Figure 3. 4).  Table 3. 2 summarizes the mean loading 
efficiency for all cell types and labeling conditions.   
Table 3. 2. Loading efficiency (fluorine atoms per cell) of the PFC probe were determined based on NMR spectra 
peaks (shown in Figure 3.4) of the cell pellets relative to a TFA reference. 
   
Estimated F/cell 
 Cell Sense Concentration 
Cell Type 1.5 mg/mL 3.0 mg/mL 
THP-1 macrophage-like 
(n = 3) 
9.84 x 1012 1.39 x 1013 
CRC-grown HBE (n = 3) 1.24 x 1013 3.16 x 1012 
Murine BMM (n = 2) 9.20 x 1013 - 
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Figure 3. 5a shows HBE labeled cell pellets (1 x 106 and 4 x 106), that were imaged 
approximately 24 hours after washing using 19F MRI techniques.  Figure 3.5b shows the 
correlation between cell number per mm3-voxel and normalized signal-to-noise ratio (SNR) for 
each cell phantom.  An estimate for the minimum number of HBE progenitor cells per mm3-
voxel needed to produce a visible signal— 4.0 x 103 cells/voxel— was estimated from the 
correlation between cell quantity and SNR. 
Figure 3. 6. Cells are efficiently labeled with the PFC 
probe ex vivo. 19F NMR spectra for pelleted and 
labeled (3 x 106 cells, 1.5 mg/mL Cell Sense for 24 
hours) (a) macrophage-like THP-1 cells, (b) CRC-
grown HBEs, and (c) murine BMMs. 
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Figure 3. 7.19F MRI Phantom studies (a) were acquired using previously outlined imaging parameters on two cell 
phantoms containing 1 x 106 and 4 x 106 cells, respectively.  The “R” designated the Cell Sense reference phantom; 
(b) Signal  normalized to a 1 mm3-voxel was calculated from 19F MRI and correlated to cell quantity per voxel for cell 
quantification purposes.  Cell quantification was validated by (c) the actual versus quantified cell number per voxel.  
The Pearson correlation coefficient is 0.99. 
Parkinson’s Disease Mouse Model Results 
Cell viability and PFC probe loading efficiency studies were conducted on murine BMM.  
Toxicity experiments (Figure 3. 6) showed some impact on cell survival rate based on Cell Sense 
concentration levels in incubation media.  ANOVA analysis revealed a significant difference in 
toxicity due to differing Cell Sense concentrations (p = 0.00252), and subsequent pairwise t-tests 
determined that only cells incubated in 3.0 mg/mL Cell Sense experienced significantly lower 
survival rates.  19F NMR analysis of pelleted labeled BMM (Figure 3. 4c) was used to determine 
cell PFC-loading efficiency and validate cellular uptake of Cell Sense (Table 3. 2). 
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Ex vivo PFC-labeled cells were injected into mice either intravenously (2 x 106 cell/200 
μL) or intraventricularly (2 x 105 cell/5 μL).  Figures 3. 7 a and 3. 7 d show the proton images of 
axial slices for each mouse, acquired 24 hours after injection (day 1).  Corresponding 19F images 
are shown in Figures 3. 7 b and 3. 7 e, where only the reference phantom and injected cells were 
detectable.  The overlay between the proton and fluorine images are show in Figures 3. 7 c and 3. 
7 f, allowing for localization of injected cells in the mouse body. 
  
Figure 3. 8. Toxicity experiments conducted after 24 hours of incubation demonstrate that the highest labeling 
concentration used for murine macrophages was the only labeling condition that significantly increase cell toxicity. 
In vivo 19F signal was tracked over time, yielding a decrease over time in the total 
estimated number of cells present intracranially (Table 3. 3). 
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Table 3. 3. The number of labeled BMMs present in mice was quantified over time in each mouse. 
 
 
  
 Intraventricular Cell Injection 
Intravenous 
Cell Injection 
 2 hours post-
injection (day 0) 
24 hours post-
injection (day 1) 
120 hours 
post-injection 
(day 5) 
24 hours post-
injection (day 1) 
Estimated Number of 
Cells (intracranial) 
2.7 x 105 1.3 x 105 5.0 x 104 2.7 x 105 
Estimated Number of 
Cells (extracranial) 
- 1.4 x 105 3.7 x 104 3.3 x 105 
Total Estimated 
Number of Cells 
2.7 x 105 2.7 x 105 8.7 x 104 6.1 x 105 
 
 
Figure 3. 9.  Representative axial proton (a and d), fluorine (b and e), and overlay (c and f) images with 19F signal 
rendered in “hot metal” color scale on the day after cell injection.  The green arrows point to intracranial Cell Sense-
labeled BMM, while extracranial murine macrophages are demarcated by yellow arrows. “R” designates the 
reference phantom.  The mouse depicted in a though c received 2 x 105 cell intraventricularly and was imaged 24 
hours after the introduction of cells.  The lower panel (d through f) shows a mouse that received 2 x 106 cells 
intravenously and was imaged 24 hours after the cell injection. 
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Discussion 
These studies evince efficient labeling of multiple cell types with a PFC probe with some 
effect on cell viability.  These results are supported by previous investigations [22-24] that show 
the ability of PFPE-marker loading with minimal impact on cytotoxicity.  19F MRI signal 
detectability was demonstrated in vitro and in vivo using Cell Sense, an FDA-approved cellular 
imaging agent.  An alternative cell tracking method is superparamagnetic iron-oxide (SPIO) 
MRI, wherein SPIO nanoparticles serve as contrast labeling agent for cells as a method to exploit 
the advantages of MRI for cell tracking [24-28].  Cells labeled ex vivo or in situ with SPIO 
experience a significant shortening of T1 and T2 relaxations times of those cells relative to their 
environment, thus allowing for the observation cellular contrast changes by MR imaging [26].  
While metal-ion cell labeling offers increased sensitivity, its drawbacks include complex cell 
number quantification and biocompatibility issues [24, 25]. Furthermore, as a negative contrast 
technique, its application in the high susceptibility region such as the lung, is limited.  Current 
methods of imaging inflammation and the inflammatory response are limited to anatomical 
images of tissue to capture visible changes [29].  Conventional imaging modalities are limited in 
their ability to visualize inflammation by spatial resolution and tissue penetration depth.  
Consequently, inflammation imaging by anatomical methods often provides information in the 
late stages of inflammation—when the damage often becomes permanent [1, 29].  PFC labeling 
of inflammatory cells allows for the visualization and quantification of inflammatory cells, 
providing researchers with information on the early inflammatory response.  Early imaging of 
inflammation is the gateway for diagnostic inflammation markers and the quantification of 
inflammation in subjects over time [1].  This is the first study to apply 19F MRI techniques for 
inflammation imaging and cell tracking purposes in CF and PD models. 
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Cytotoxicity, Labeling Efficiency, and 19F MRI cell detection for CF models 
Fluorescence imaging, fluorescence measurements, and 19F NMR demonstrated the 
uptake of Cell Sense by THP-1 macrophage-like cells and CRC-grown HBE progenitor cells, 
with little impact on cell viability.  Due to the phagocytic behavior of macrophages, a higher 
labeling efficiency was expected for THP-1s versus HBEs, however 19F NMR uptake validation 
studies revealed that this was not the case for the one (1.5 mg/mL, 24-hour incubation) labeling 
condition. 
As HBEs are a likely candidate for future cell therapy investigations, this study focused 
on the determination of SNR limits for PFC-loaded HBE progenitor cells.  In vitro 19F MRI of 
labeled HBEs demonstrated the capability to image at least 4.0 x 103 cells/voxel to provide 
visible signal.  Current imaging parameters may prove to be a limitation for future studies, which 
require in vivo imaging of labeled therapeutic bronchial epithelial cells engrafted onto injured 
mice tracheas and other levels of the airway tree.  Such studies would likely not involve such 
high labeled-cell counts in murine models.  Future studies may require the use of alternative MRI 
sequences more optimized for 19F MRI cell tracing.  Notwithstanding, fluorine imaging methods 
in this study proved to be capable of cell quantification in vitro.  The HBE cell quantification 
experiments showed a strong correlation between measured cells/voxel and actual cells/voxel. 
 19F MRI in a PD murine model 
19F NMR studies demonstrated cellular uptake of the Cell Sense labeling agent.  Unlike 
the THP-1 macrophages, the murine bone marrow-derived macrophages higher labeling 
concentrations negatively impacted viability, necessitating the use of a more dilute labeling 
condition for further studies (1.5 mg/mL, 24-hour incubation).  This difference in viability can 
potentially be attributed to the ≈7-fold and ≈9-fold increase in loading efficiency by BMM as 
compared to HBE progenitor cells and THP-1 macrophages, respectively. 
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This study demonstrated in vivo 19F MRI inflammation imaging of labeled BMMs in 
murine PD models, and sufficient SNR was achieved for the detection of PFPE-labeled cell by 
19F MRI.  Both mice were imaged at the time point when LPS-induced inflammation was 
anticipated to be the greatest (48 hours after LPS injection, i.e. 24 hours after PFC-labeled cells 
were introduced).  Additional time points were explored for the mouse that received an 
intraventricular labeled-cell injection to allow for cell tracking over time.  These results show 
that the number of labeled cells decreased overtime, with the exception of extracranial cells from 
day 0 to day 1 (Table 3. 3).  As labeled cells migrated out of the brain— and presumably entered 
circulation— on the day of labeled cell injection, the fluorine signal originating outside of brain 
space increased.  Additional labeled-cell delivery models as well as an increase in sample size 
will be necessary for future studies.  These results act as a proof-of-concept, and further 19F MRI 
cell tracking investigations with a greater number of mice, experimental and control conditions is 
necessary. 
Conclusion 
Moving forward, it will be necessary to conduct further investigations to further 
substantiate the use of 19F MRI for cell tracking and inflammation imaging in small animal 
models.  Confirmation of targeted delivery of the therapeutics to the desired site will through 
alternative more established means (ex. fluorescence imaging of fixed histological slides) will be 
necessary.  
Studies conducted in this chapter have shown that 19F MRI methods can be employed to 
detect and track fluorine-labeled cells in two different murine disease models.  These studies 
demonstrated the proof-of-concept for the application of 19F MRI in in vivo cell tracking and 
inflammation imaging, which are critical tools for cell therapy research in disease models where 
inflammatory response impact disease progression.  While continuing investigations are 
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necessary to improve this technique, thus far it is clear that 19F MRI provides the ability to study 
cell biodistribution and inflammatory response using preclinical small animal models at high 
magnetic fields.   
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CHAPTER FOUR: CONCLUSION 
The investigations included in this thesis incorporate the implementation of 19F MRI 
techniques to achieve their respective goals of human pulmonary ventilation imaging and in vivo 
cell tracking and inflammation imaging.  The ability to perform 19F MRI relied heavily on 
applying conventional proton MRI techniques in a multinuclear setting.  This was feasible at a 
relatively low cost because 1H and 19F isotopes have resonances within 6% of each other.  
Existing clinical scanners are easily equipped with 19F or dual-tune 1H/19F coils to perform 19F 
magnetic resonance imaging.  Additionally, commercially available fluorinated compounds are 
widely available.  Compounds such as PFP and Cell Sense have been investigated for a number 
of years and are well characterized for in vivo use in humans and animals commonly used in 
disease modeling [1-4].  These compounds demonstrated the ability to function as chemically 
inert, non-toxic 19F contrast agents in a number of applications. 
19F MRI of pulmonary ventilation in healthy human volunteers and volunteers with CF 
experiments illustrated the potential to use this technique for functional imaging of the lungs. 
Similarly, the cell tracking studies explored here established the feasibility and utility of this 
technique for use in an in vivo CF and PD mouse model.  Future development of pulse sequences 
will improve the use of 19F for these applications, especially for ventilation imaging where 
current image acquisition requires breath-holds.   Additionally, ongoing development in the 
improvement of labeling agents will further improve SNR and reduce image acquisition times 
for in cell tracking experiments.   
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Overall, these studies established that 19F MRI techniques can perform pulmonary 
ventilation imaging and in vivo cell tracking and inflammation imaging in humans and small 
animals. 
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